Joshua Kantrowitz, MD

  • 2Articles
  • 2025Active

About

Joshua Kantrowitz, MD, has published research on emerging treatments for schizophrenia, focusing on the management of negative symptoms and the development of muscarinic agonists and modulators targeting M1 and M4 receptors. His work, appearing in Psychiatrist.com in 2025, addresses advances in pharmacological approaches within this clinical area.

Publications

JCP
Update on Current & Emerging Treatments for Negative Symptoms in Schizophrenia
Insights

Update on Current & Emerging Treatments for Negative Symptoms in Schizophrenia

February 21, 2025

In this video, Dr. Kantrowitz provides an in-depth update on current and emerging treatments for the negative symptoms of schizophrenia. He discusses symptom classifications, key clinical trials, and potential...
JCP
The Near-Term Future of Muscarinic Agonists and Modulators for Schizophrenia: M1 and/or M4
Insights

The Near-Term Future of Muscarinic Agonists and Modulators for Schizophrenia: M1 and/or M4

February 21, 2025

In this video, Dr. Kantrowitz explores the potential of muscarinic acetylcholine receptor (mACHR) agonists and modulators for schizophrenia treatment, with a focus on M1 and M4 receptors. He reviews...

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe